FY2024 Earnings Estimate for Immunic Issued By HC Wainwright

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Immunic in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.95) for the year. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Immunic's FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

A number of other brokerages also recently commented on IMUX. EF Hutton Acquisition Co. I raised shares of Immunic to a "strong-buy" rating in a research note on Monday, September 16th. B. Riley assumed coverage on Immunic in a research note on Tuesday, August 27th. They set a "buy" rating and a $6.00 price objective on the stock. Leerink Partners reaffirmed an "outperform" rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. Leerink Partnrs upgraded Immunic to a "strong-buy" rating in a report on Monday, September 9th. Finally, StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $11.80.

Immunic Price Performance

IMUX stock traded up $0.06 during midday trading on Wednesday, reaching $1.20. 720,334 shares of the company's stock traded hands, compared to its average volume of 624,698. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The business has a 50-day moving average price of $1.37 and a two-hundred day moving average price of $1.34. The company has a market capitalization of $108.09 million, a P/E ratio of -0.98 and a beta of 1.88.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now directly owns 87,300 shares of the company's stock, valued at approximately $100,395. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently bought and sold shares of IMUX. Virtu Financial LLC bought a new position in Immunic during the 1st quarter valued at $25,000. Jane Street Group LLC boosted its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after acquiring an additional 42,383 shares during the period. State Street Corp raised its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. Finally, Ikarian Capital LLC lifted its holdings in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.